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Background: Lung adenocarcinoma is a heterogernous disease that creates challenges for classification and
management. The purpose of this study is to identify specific miRNA markers closely associated with the survival of
LUAD patients from a large dataset of significantly altered miRNAs, and to assess the prognostic value of this
miRNA expression profile for OS in patients with LUAD.
Methods: We obtained miRNA expression profiles and corresponding clinical information for 372 LUAD patients
from The Cancer Genome Atlas (TCGA), and identified the most significantly altered miRNAs between tumor and
normal samples. Using survival analysis and supervised principal components method, we identified an eight-miRNA
signature for the prediction of overall survival (OS) of LUAD patients. The relationship between OS and the identified
miRNA signature was self-validated in the TCGA cohort (randomly classified into two subgroups: n = 186 for the training
set and n = 186 for the testing set). Survival receiver operating characteristic (ROC) analysis was used to assess the
performance of survival prediction. The biological relevance of putative miRNA targets was also analyzed using
bioinformatics.
Results: Sixteen of the 111 most significantly altered miRNAs were associated with OS across different clinical
subclasses of the TCGA-derived LUAD cohort. A linear prognostic model of eight miRNAs (miR-31, miR-196b,
miR-766, miR-519a-1, miR-375, miR-187, miR-331 and miR-101-1) was constructed and weighted by the importance
scores from the supervised principal component method to divide patients into high- and low-risk groups. Patients
assigned to the high-risk group exhibited poor OS compared with patients in the low-risk group (hazard ratio
[HR] = 1.99, P <0.001). The eight-miRNA signature is an independent prognostic marker of OS of LUAD patients and
demonstrates good performance for predicting 5-year OS (Area Under the respective ROC Curves [AUC] = 0.626,
P = 0.003), especially for non-smokers (AUC = 0.686, P = 0.023).
Conclusions: We identified an eight-miRNA signature that is prognostic of LUAD. The miRNA signature, if validated in
other prospective studies, may have important implications in clinical practice, in particular identifying a subgroup of
patients with LUAD who are at high risk of mortality.
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Lung adenocarcinoma (LUAD), is the most common histo-
logical subtype of non-small cell lung cancer (NSCLC) in
females (smokers or non-smokers), and in non-smoking
males. The incidence of LUAD has increased markedly
over the past few decades in many countries, including
China [1,2]. Most adenocarcinomas first occur in the outer
region of the lungs with a tendency to spread to the lymph
nodes and beyond. Despite advances in diagnosis and
treatment, lung cancer mortality has increased. Mortality
rates are amongst the highest of any cancer type.
Following advances in genomics, proteomics and mo-
lecular pathology, many candidate biomarkers with po-
tential clinical value have been identified [3]. Further
development of genomic biomarkers is expected to im-
prove patient stratification and lead to more personalized
treatment. MicroRNAs (miRNAs, miRs) are small, non-
coding RNAs of 18–25 nucleotides, and are thought to
regulate gene expression post-transcriptionally by causing
mRNA degradation and/or repressing mRNA translation
[4]. MiRNAs are frequently dysregulated in cancer, and
may function as both oncogenes and tumor suppressors
[4,5]. Several prognostic and predictive miRNA markers
have been identified for NSCLC [6-11]. However, owing to
the small datasets used, the heterogeneous nature of the
disease and pre-selection of miRNAs and variations in the
approaches for data pre-processing, there are inconsisten-
cies in these sets of miRNA markers.
The purpose of this study is to identify specific miRNA
markers closely associated with the survival of LUAD
patients from a large dataset of significantly altered miR-
NAs, and to assess the prognostic value of this miRNA
expression profile for OS in patients with LUAD.
Methods
TCGA miRNA dataset and patient information
MiRNA expression data and corresponding clinical data
for 448 LUAD patients were obtained from The Cancer
Genome Atlas (TCGA) data portal (January 2013) [12].
Both the miRNA expression data and clinical data, includ-
ing outcome and staging information of TCGA LUAD pa-
tients deposited at the Data Coordinating Center (DCC),
are publically available and open-access. TCGA data are
classified by data type (clinical, mutations, gene expression)
and data level, to allow structured access to this resource
with appropriate patient privacy protection. This study
meets the publication guidelines provided by TCGA [13].
The expression of 1046 human miRNAs in LUAD samples
was assessed using the Illumina HiSeq Systems (n = 385)
and Genome Analyzer (n = 63). MiRNA expression profiles
for normal lung tissues (n = 46) were also analyzed using
the Illumina HiSeq System. Level 3, normalized miRNA
expression data (the calculated expression for all reads
aligning to a particular miRNA per sample) were collectedfrom the TCGA Data Portal using the Data Browser tool
and quantile normalized [14], before performing down-
stream analysis. Samples and corresponding clinical data
were cross-referenced by tumor barcodes. Owing to pos-
sible unrelated causes of death, 76 patients with an overall
survival (OS) of less than 1 month were removed from the
analysis. A total of 372 LUAD patients, including 196 fe-
males (mean age 66.23 ± 9.44 years) and 176 males (mean
age 65.69 ± 9.94 years), were enrolled in the study (median
follow-up: 15.23 months). To validate the miRNA markers
being a specific signature or panel for LUAD, the data of
TCGA lung squamous cell carcinoma (lung SCC), (321 pa-
tients) were also downloaded.
Identification of differentially expressed miRNAs in LUAD
and normal lung tissue samples
To identify miRNAs differentially expressed between
LUAD and normal lung tissues, the raw counts of TCGA
miRNA expression (level 3 data) obtained from the TCGA
dataset (Illumina HiSeq Systems,385 LUAD samples
and 46 normal controls) were normalized by a weighted
trimmed mean of the log expression ratios (Trimmed
mean of M values method, TMM) [15] using the R/Bio-
conductor package of edgeR [16]. Since many miRNAs
were not expressed in certain tissue types or showed little
variation over the patients in the dataset, only miRNAs
expressed in at least two normal or tumor samples, with
at least 100 counts per million were retained in the profile.
A generalized linear model (GLM) was used to remove
the batch effect. The expression differences were cha-
racterized by logFC (log 2 fold change) and associated
P- values. LogFC indicates the fold change in expression of
each miRNA from LUAD to normal lung tissue. Down-
and up-regulated miRNAs were assigned a logFC < −1 and
logFC >1 respectively, with FDR-adjusted P < 0.05.
Survival analysis
A univariate Cox model was used to investigate the rela-
tionship between the continuous expression level of
each miRNA and OS within different independent clas-
ses of disease stage, lymph node involvement (N stage),
neoplasm metastasis (M stage), and size of original
(primary) tumor (T stage). The Kaplan-Meier and log-
rank method (Mantel-Haenszel test) were performed to
test the equality for survival distributions in different
groups. Hazard ratios (HRs), the ratio of hazards for a
2-fold change in the gene expression level, from univariate
Cox regression analysis were used to identify candidate
miRNAs associated with OS. MiRNAs with a HR < 1
were defined as a protective signature and those with
HR for death > 1 were defined as high-risk miRNAs.
The Cox proportional hazard model was used for multi-
variate analysis to identify miRNAs profiles or covari-
ates with independent prognostic value.
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Univariate survival analyses were used to identify com-
mon miRNA related to OS within each of the following
independent classes: disease stage, N stage, M stage and
T stage. Within each group of clinical characteristics,
the patient subclasses represented non-overlapping sets.
Common miRNAs associated with OS in at least two in-
dependent categories for each covariate were selected as
candidate markers, using a P-value of 0.1 as the cutoff
for miRNA selection. The self-validated method (186
randomly selected samples as the training set and the
other 186 samples as the validated set) was used to de-
velop a prognostic model of the weighted linear com-
bination of the detected miRNA expression levels. This
algorithm is based on an importance score assigned
to each miRNA, calculated by the supervised principal
components method [17] and using the 10-fold cross-
validation for selection of significant miRNAs. The prog-
nostic score was calculated as follows: Prognostic-score =
(0.181 × expression level of miR-31) + (0.136 × expression
level of miR-196b) + (−0.114 × expression level of miR-
375) + (−0.148 × expression level of miR-187) + (−0.352×
expression level of miR-331) + (−0.372× expression level
of miR-101-1) + (0.182× expression level of miR-766) +
(0.21× expression level of miR-519a-1).
We used the linear miRNA prognostic model obtained
from the training set to calculate an eight-miRNA signa-
ture prognostic score for each of the 372 patients. From
the eight-miRNA signature prognostic scores we classified
the samples into high-risk or low-risk group using the me-
dian score from the training set as a cutoff. Kaplan-Meier
survival curves for the cases predicted to have low or high
risk were generated. The prognostic performance was
measured using time-dependent receiver operating char-
acteristic (ROC) curves [18] by comparing the area under
the respective ROC curves (AUC). Since the majority of
events occurred before 60 months, the ability of models to
predict outcome at and around 60 months was assessed.
Permutation P-values of AUC were calculated from 1000
permutations of the survival data.
The prognostic value of the miRNA signature for OS
of patients in the early stage of disease or with different
smoking status was also assessed using the survival ROC
analysis. We also validated the prognostic utility of the lin-
ear miRNA prognostic model in TCGA lung SCC patients.
To evaluate the contribution of miRNAs as independ-
ent prognostic factors of patient survival, we used a
multivariate analysis. All variables reaching a significant
level of 10% in univariate analyses were tested in a Cox
proportional hazards model. All reported P values were
two-sided. All analyses were performed using the R/Bio-
Conductor (version 3.0.2) [19] and survival curves and
ROCs were generated by ggplot2, survMisc and survi-
valROC [20] packages.In silico analysis of pathways specifically targeted by the
prognostic miRNAs in LUAD
We examined whether altered miRNA expression associ-
ated with OS had a functional effect on the progression of
LUAD. The miRWalk online database [21], which offers a
comparative platform of possible miRNA-target predictions
using 10 different data sets in addition to validated targets,
was used to predict target genes of the eight miRNAs. The
target gene was selected if it was predicted by at least three
data sets using miRanda, miRDB, miRWalk, PITA, RNA22
and Targetscan programs. Over-representation analysis
(ORA) was performed using the GeneTrail gene set ana-
lysis tool [22,23] with default settings to detect the potential
biological terms or functional effect categories represented
in the target gene list. The P values for the biological cat-
egories were adjusted by FDR and were considered statisti-
cally significant at P < 0.05.
Results
Identification of differentially expressed miRNAs in LUAD
patients
Analysis of miRNA expression profiles in LUAD patient tis-
sues (n = 385) compared with normal lung tissues (n = 46)
identified a total of 111 differentially expressed miRNAs
(logFC > 1 or logFC < −1, P < 0.05 after FDR adjustment),
which were used for subsequent survival analyses
(Additional file 1: Table S1). Of these, 82 miRNAs were
over-expressed including miR-31 and miR-196b, which
exhibited > 8-fold increased expression. 29 miRNAs were
down-regulated, including miR-187, miR-331 and miR-101-1.
Correlation between miRNA expression, clinical features
and prognosis in the TCGA LUAD cohort
Clinical covariates for LUAD patients are summarized in
Table 1. Owing to the high censoring rate (69.35%) in the
TCGA LUAD cohort, which refers to patients who may
leave the study or are still alive at the end of the study, we
first performed univariate survival analyses. This was used
to confirm the prognostic significance of previously estab-
lished clinical parameters in the cohort, including stage,
age and other clinicopathological features.
Clinical variables of N stage, T stage, M stage and dis-
ease stage were significantly associated with OS; how-
ever, age, gender, smoking status and adjuvant treatment
were not. Kaplan-Meier survival curves for these vari-
ables are shown in the Additional file 1: Figures S1–S8.
The results of this preliminary assessment indicated that
despite the high level of censored data in this cohort, the
survival data for the TCGA LUAD cohort were inform-
ative and suitable for studying the prognostic relevance
of miRNA expression.
We next conducted univariate survival analyses to iden-
tify common miRNAs related to OS within each of the
following independent classes: disease stage, N stage, M
Table 1 Clinical covariates for the TCGA lung adenocarcinoma cohort in the training and test set
Covariates Total Training set Testing set P-value
N = 372 N = 186 N = 186
Age, years, no (%) <=65 174 (46.8) 94 (50.5) 80 (43.0) 0.1767
>65 198 (53.2) 92 (49.5) 106 (57.0)
Gender, no (%) Male 176 (47.3) 87 (46.8) 89 (47.8) 0.9173
Female 196 (52.7) 99 (53.2) 97 (52.2)
Vital status Alive 258 (69.4) 125 (67.2) 133 (71.5) 0.4311
Dead 114 (30.6) 61 (32.8) 53 (28.5)
Disease stage, no (%) I 199 (53.5) 100 (53.8) 99 (53.2) 0.9000
II 89 (23.9) 42 (22.6) 47 (25.3)
III 66 (17.7) 35 (18.8) 31 (16.7)
IV 17 (4.6) 9 (4.8) 8 (4.3)
Lymph node N0 231 (62.1) 118 (63.4) 113 (60.8) 0.6046
Involvement, no (%) N1 72 (19.4) 32 (17.2) 40 (21.5)
N2 58 (15.6) 32 (17.2) 26 (14.0)
N3 1 (0.3) 0 (0.0) 1 (0.5)
M stage, no (%) M0 266 (71.5) 131 (70.4) 135 (72.6) 0.4400
M1 16 (4.3) 10 (5.4) 6 (3.2)
T stage, no (%) T1 112 (30.1) 52 (28.0) 60 (32.3) 0.6320
T2 211 (56.7) 108 (58.1) 103 (55.4)
T3 31 (8.3) 15 (8.1) 16 (8.6)
T4 16 (8.3) 10 (5.4) 6 (3.2)
Smoking status Nonsmoker 143 (38.4) 66 (35.5) 77 (41.4) 0.3214
Smoker 217 (58.3) 113 (60.8) 104 (55.9)
Adjuvant treatment None 255 (68.5) 121 (65.1) 134 (72.0) 0.5530
Chemotherapy 68 (18.3) 37 (19.9) 31 (16.7)
Radiotherapy 20 (5.4) 13 (7.0) 7 (3.8)
Chemoradiotherapy 27 (7.3) 14 (7.5) 13 (7.0)
Other 2 (0.5) 1 (0.5) 1 (0.5)
Nonsmoker: lifetime nonsmoker or current reformed smoker for > 15 years.
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istics, the patient subclasses represented non-overlapping
sets. MiRNAs associated with OS, exhibiting a significance
level of 10% in at least two independent categories for
each covariate, were selected as candidate markers. The
respective HRs for the common miRNA expression in
each subclass are shown in Figure 1.
Eight miRNAs were selected, based on the importance
scores computed by the supervised principal component
method in the training set. A mathematical formula with
eight miRNAs was then constructed for clinical outcome
prediction. The same prognostic score formula obtained
from the training set was used to calculate the eight-
miRNA signature score for each of the 186 patients in
the testing set.
Figure 2 shows the distribution of patient prognostic
scores, the survival status and tumor miRNA expression ofall 372 LUAD patients, ranked according to the prognostic
score values for the eight-miRNA signature. Of these eight
miRNAs, four were associated with high risk (hsa-mir-31,
miR-196b, miR-766, miR-519a-1, HR > 1) and four were
shown to be protective (miR-375, miR-187, miR-331, miR-
101-1, HR < 1). Tumors with high prognostic scores tended
to express high-risk miRNAs, whereas tumors with low
prognostic scores tended to express protective miRNAs
(Figure 2B and C). Patients with high-risk scores had more
deaths than low-risk-score patients. Similar results were
observed in both the training set and the testing set. We
also compared the expression of the eight-miRNA signa-
ture between short-term (fatal within 2 years, n = 138,
those who were censored within 2 years not included) and
long-term survivors (n = 57). The eight-miRNA signature
scores between long- and short-term survivors were signifi-
cantly different (P = 0.0011). Recurrence (local or regional,
Figure 1 MiRNAs associated with prognosis in different clinical subclasses of TCGA lung adenocarcinoma cohort. The matrix visualizes
the significant HRs for the 16 miRNAs in the TCGA LUAD cohort. Numbers in the rectangles indicate the HRs for expression with significant
univariate Cox regression (P < 0.1). Red rectangles indicate HRs >1 and blue rectangles indicate HRs <1.
Figure 2 MicroRNA predictor-score analysis of 372 LUAD patients in TCGA cohort. (A) MicroRNA predictor-score distribution. (B) Patients’
survival status. (C) Color-gram of miRNA expression profiles of LUAD patients. The blue dotted line represents the median miRNA signature cutoff
dividing patients into low-risk and high-risk groups.
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LUAD cohort. High miRNAs signature score was also re-
lated to short recurrence free survival (HR = 1.262, P =
0.011) in this subset.
The median cutoff point obtained from the training
set was used for the entire TCGA LUAD patient cohort
to classify the patients into either high-risk or low-risk
groups. Comparison of clinicopathological factors in the
high- and low-risk groups (Additional file 1: Table S2) re-
vealed that the eight-miRNA signature was significantly
correlated with lymph node metastasis (P = 0.0085) and
clinical stage (P = 0.0252). Patients expressing the high-risk
miRNA signature exhibited poorer OS than patients ex-
pressing the low-risk miRNA signature (median OS of
39.0 months vs. 59.3 months, HR = 1.99, P value < 0.001).
Kaplan-Meier curves for the high-risk and low-risk groups
within the TCGA LUAD cohort (n = 372) are shown in
Figure 3A. Time-dependent ROC curves were used to as-
sess the prognostic power of the eight-miRNA signature.Figure 3 Kaplan–Meier and ROC curves for the 8-miRNA signature in
groups obtained from the TCGA cohort (n = 372) divided by the median cu
(Median OS: 39.0 months vs. 59.3 months, P < 0.001). (B) The ROC curve ha
from 1,000 permutations for testing the null hypothesis (AUC = 0.5).The AUC for the eight-miRNA signature prognostic model
was 0.626 at 60 months of OS (P = 0.003, Figure 3B). How-
ever, eight-miRNA signature was not significantly associ-
ated with OS of lung SCC patients (HR = 1.200, P = 0.380)
and the AUC was 0.522 (P = 0.397).
Independent prognostic value of miRNA signatures
Since patients at the early tumor stage may benefit sig-
nificantly from a prognostic biomarker signature, we also
evaluated the prognostic power of the eight-miRNA sig-
nature in stage I and II LUAD tumors (n = 288). This
signature also demonstrated good performance on early
tumors (AUC = 0.605, permutation P = 0.027, Additional
file 1: Figure S9).
Surprisingly, although there was no relationship between
smoking status and OS in the TCGA LUAD cohort, the
eight-miRNA signature exhibited superior prognostic value
for patients who were non-smoking or reformed smokers
for more than 15 years (n = 145). The AUC at 60 monthsTCGA LUAD cohort. (A) The Kaplan–Meier curves for LUAD risk
toff point. Patients with high scores had poor outcome in terms of OS
d an AUC of 0.626 (P = 0.003). The permutation P value was obtained
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of 0.023 (Figure 4). Further analysis indicated that
smoking status was significantly related to age (P = 0.000,
Additional file 1: Table S3); however, the AUC for the
younger population (diagnosed before 65 year-old) was
not better than that for the entire cohort (AUC = 0.593,
P < 0.05).
We also conducted a multivariate analysis to evaluate
the independent prognostic value of the eight-miRNA
signature. All variables reaching a significant level of
10% in univariate analyses were tested in a Cox propor-
tional hazards model. The miRNA signature, T stage, N
stage and M stage were used as covariates and age was
also included into the multivariate model as a potential
confounding risk factor. Tumor stage was not included
owing to its interaction with TNM staging system. This
analysis revealed that the miRNA signature (HR =
1.493, P < 0.001) and the lymph node involvement (N
stage) (HR = 2.607, P < 0.001) are independent prog-
nostic factors associated with OS (Additional file 1:
Table S4).Figure 4 Kaplan–Meier and ROC curves for the 8-miRNA signature in
LUAD risk groups obtained from the TCGA non-smoking LUAD cohort (n =
high scores had poor outcome in terms of OS (Median OS: 46.0 months vs
(P = 0.023). The permutation P value was obtained from 1,000 permutationIn silico analysis of pathways specifically targeted by the
prognostic miRNAs in LUAD
We used GeneTrail to identify functional categories among
target genes that could be predicted by the selected
miRNAs. A total of 7686 target genes were identified as
potentially regulated by miRNAs contained in the eight-
miRNA signature. We performed an ORA to test the
specific functional categories of genes from Kyoto Ency-
lopedia of Genes and Genomes (KEGG) categories and
852 Gene Ontology (GO) categories that are targeted by
miRNAs. It revealed enrichment of 55 KEGG categories
and 852 GOcategories (P-values < 0.05 after FDR adjust-
ment, Additional file 1: Table S5). This analysis revealed
an overrepresentation of the predicted miRNA targets
involved in the critical pathway linked to tumor-promoting
function such as: focal adhesion, adherens junction,
apoptosis, Ras protein signal transduction, and p53 sig-
naling pathway We observed an overlap of target genes
enriched in cancer-related KEGG categories of NSCLC
and small cell lung cancer (SCLC). These indicate a po-
tentially important functional role of selected miRNAsTCGA non-smoking LUAD cohort. (A) The Kaplan–Meier curves for
145) divided by the median cutoff point. Non-smoking patients with
. 59.3months, P = 0.027). (B) The ROC curve had an AUC of 0.686
s for testing the null hypothesis (AUC = 0.5).
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validated target genes (obtained from miRWalk) in-
volved in the pathways related to tumor-promoting
function with highly significant P-values were shown in
Table 2. Taken together, these exploratory analyses sug-
gest that variation in miRNAs expression might affect
the critical pathways involved in LUAD progression, an
important mechanism warranting follow-up research.
Discussion
In this study, we identified 16 miRNAs correlated with OS
of LUAD patients in different clinical classes, from the 111
most significantly altered miRNAs in LUAD tissues com-
pared with normal lung tissues. A linear combination of
eight miRNAs (miR-31, miR-196b, miR-766, miR-519a-1,
miR-375, miR-187, miR-331 and miR-101-1) was validated
as an independent predictor for LUAD patient survival.
This signature demonstrated significant prognostic per-
formance in both the entire LUAD cohort and the early
stage subgroup, particularly in the non-smoking or re-
formed smoker (more than 15 years) group. Our resultsTable 2 Results of the over-representation analysis of the pre
Subcategory name P-value (FDR) Expected Observed I
NSCLC 0.00336054 21.2903 34
SCLC 0.00918204 33.1182 47
Apoptosis 0.00558373 34.6953 50
p53 signaling pathway 0.0149892 27.2043 39
Ras protein signal transduction 2.20423e-07 87.7829 131suggest that there is a potential role for miRNAs in the
molecular pathogenesis, clinical progression and prognosis
of LUAD, and highlights the potential of miRNA profiling
to improve clinical prognosis in patients with LUAD.
LUAD, constitutes about 30 - 40% of NSCLC, and is a
global public health problem, representing the most com-
mon cause of cancer-related death [1]. Owing to immense
heterogeneity from multiple aspects (pathology, molecular,
clinical, radiology and surgery)observed in LUAD patients,
the development of individualized cancer treatment and
prediction of patient outcome have been huge challenges
[24]. In the past decade, several molecular markers and
models have been proposed or developed within specific
NSCLC subgroups. In particular, the identification of
driver mutations in the EGFR and anaplastic lymphoma
kinase (ALK), introduced a new era of targeted therapy in
LUAD [25,26]. Treatment choice and monitoring of pa-
tient outcome based on the analysis of mutations in other
key biomarkers including Her2, PIK3CA, BRAF, NUTM1,
MET, ROS1, FGFR1, KRAS and PTEN may also have a po-
tentially powerful clinical impact [27-29]. Furthermore,dicted target genes
nvolved experimentally validated target genes of the prognostic
miRNA




miR-375 AKT2 CDK6 PDPK1
miR-101-1 CDKN2A PRKCA




miR-101-1 ITGA2 ITGA3 ITGAV










miR-31 CDKN2A FGF2 KRAS TIAM1 TP53
miR-187 KRAS
miR-375 MAPK3 MAPK14
miR-101-1 BCR CDKN2A CSF1
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also been used to classify or predict prognosis in patients
with lung cancer. Owing to the large numbers of genes
and the low prevalence of mutations, it may be more ef-
fective to use miRNA rather than gene expression profiles,
to classify various cancer subtypes [30]. MiRNAs are
small, conserved non-coding regulatory RNAs in humans,
and they play important roles in carcinogenesis. Each
miRNA may post-transcriptionally regulate hundreds of
downstream genes by targeting the 3’ untranslated region
of specific messenger RNAs for degradation or transla-
tional repression [5,31]. While still in the early stages of
clinical development, miRNA-expression profiling of pri-
mary tumors has already demonstrated significant promise
in clinical stratification and monitoring of therapy [32].
Several groups have identified miRNA signatures cap-
able of predicting clinical outcome in NSCLC patients. In
one miRNA profiling study based on a cohort of 357 stage
I NSCLC patients, a miRNA expression signature contain-
ing 27 miRNAs was identified that was capable of accur-
ately predicting which stage I LUAD patients may benefit
from more aggressive therapy [10]. A study of 112 NSCLC
patients (57 squamous cell carcinoma [lung SCC] and 60
LUAD, stage I- III, Asian patients) identified a five-miRNA
signature (including miR-221, let-7a, miR-137, miR-372
and miR-182∗) as an independent predictor of cancer
relapse and survival [7]. Another study, screening serum
miRNAs using Solexa sequencing, followed by a self-
validated study of 303 patients, identified miR-486, miR-
30d, miR-1 and miR-499 as non-invasive predictors of OS
in NSCLC [6]. Boeri et al. also found that higher levels of
miR-429 correlated with a worse disease-free survival in
lung cancer [33]. A recent study confirmed three novel
miRNAs (miR-662, miR −192 and miR −192*) as prognos-
tic for distant relapse in operable lung SCC [34]. In
addition, miR-708 was shown to be associated with poor
survival in LUAD from patients who had never smoked
[11]. On the basis of these studies, miRNA profiling has
already demonstrated significant potential as a prognostic
indicator in lung cancer. However, it should be noted that
there was little overlap between the miRNAs identified as
prognostic predictors of disease progression or outcome in
these various studies, indicating that comprehensive valid-
ation of miRNAs identified in these screens is necessary.
These inconsistencies may be caused, at least in part,
by fundamental, methodological differences in the pre-
selection of candidate miRNAs. In this study, TMM
normalization and the GLM method (which accounts
for the sampling properties of RNA-seq data and the
batch effect, respectively) were used to obtain differen-
tially expressed miRNAs between tumor and normal
tissues. Moreover, we obtained the candidate miRNAs
from a list of differentially expressed miRNAs between
LUAD and normal samples. This method ensured thatthe prognostic microRNA signature had statistically al-
tered expression in LUAD and also had a prognostic im-
pact on survival. However, miRNAs associated with OS
and those related with occurrence of LUAD may not
completely overlap. It is another reason for the discrep-
ancy in miRNAs identified between various studies. The
discrepancy may also be due to differences in sample
size, individual patients or the study population or the
different platforms used. Since miRNA expression pro-
files strongly differ between LUAD and lung SCC [8],
the LUAD-specific target miRNAs identified in this
study may have further potential application in predict-
ing the clinical outcome in patients with LUAD and re-
vealing targets for the development of therapy.
In this study, we selected only common miRNAs re-
lated to clinical outcome in the non-overlapping sub-
classes, from the same class as the potential prognostic
miRNAs. For this reason, several of the miRNAs previ-
ously identified as being associated with OS in lung can-
cer were not obtained, since they were only significant
within a single subclass in the TCGA cohort. Among
the eight miRNAs, miR-31 has been validated as a marker
for lymph node metastasis in lung cancer [35]. MiR-31 has
been shown to act as an oncogenic miRNA by targeting
specific tumor suppressors, including the large tumor sup-
pressor 2 (LATS2) and PP2A regulatory subunit B alpha
isoform (PPP2R2A) [36], its high expression has been as-
sociated with poor survival of lung SCC [37]. In contrast,
in a study of 164 NSCLC patients, low miR-375 expression
in plasma was associated with worse OS [9]. Down regula-
tion of miR-375 in tissues was also significantly associated
with poor outcome in patients with esophageal SCC [38].
It was proved that miR-101 expression was significantly
associated with pathological stage and lymph node in-
volvement, and might play an important role as a bio-
marker for prognosis and therapeutic targets of NSCLC
[39], (through directly targeting enhancer of zeste homo-
log 2(EZH2) [40]). For the remaining five miRNAs, to our
knowledge, there are no associations reported between
these and OS in lung cancer. MiR-196b has been identi-
fied as a biomarker, capable of distinguishing lung SCC
and LUAD [41]. It also demonstrates potential prognostic
value for disease progression in gastric cancer and glio-
blastoma [42,43]. Although there was no obvious evidence
of an association between miR-196b and OS in lung can-
cer, Annexin A1, one of several validated miR-196b target
genes, has been identified as a pro-invasive and prognostic
factor for in LUAD [44]. Ectopic expression of miR-187
was reported to lead to a significantly more aggressive
phenotype in breast cancer cells and clear cell renal cell
carcinoma [45,46]. Deregulation of miR-519a-1, regulated
by phospho (p)-ΔNp63α, in head and neck SCC cells, led
to the subsequent modulation of several target mRNAs
including TP73, YES1, PARP1, HIPK2, ATM, CDKN1A,
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involved in apoptotic processes [47]. Similarly, overexpres-
sion of miR-766 was shown to significantly inhibit the
expression of pro-apoptotic genes caspase-3 and Bax in
acute promyelocytic leukemia cells [48]. Previous studies
have also shown that miR-331-3p, a member of miR-331
family, may be involved in cell cycle control by targeting
the 3′-untranslated region of the cell cycle-related mol-
ecule, E2F1 [49]. The ORA in this study also revealed
a significant enrichment of miRNA targets involved in
NSCLC and SCLC KEGG pathways. Genes involved in
apoptosis/regulation of cell cycle, the categories which
were enriched within the target genes of our eight miR-
NAs, are implicated in LUAD tumorigenesis and represent
potential therapeutic targets [50]. Several genes involved
in these pathways, such as AKT2, TP53 and TNF, have
been identified as the key biomarker of LUAD prognosis
[51-53]. Our in silico pathway enrichment analysis based
on the predicted target mRNA genes, suggested that vari-
ation in miRNAs expression might affect critical pathways
involved in LUAD progression. Since all target prediction
algorithms generate certain fraction of both false positives
and false negatives, further research is warranted.
Lung cancer in non-smokers has recently been recog-
nized as a distinct disease entity, owing to the striking
demographic, clinicopathological and molecular differ-
ences between lung cancer in never-smokers and ever-
smokers [54,55]. Due to its prominence in Asian countries
and increasing trend in most developed countries [56], in-
vestigations and clinical trials should be undertaken to
determine the underlying causes and factors affecting pro-
gression of non-smoking-related lung cancer.
Several studies have linked smoking to poor outcomes
among patients with lung cancer [57-59]. However in
TCGA LUAD cohort, there was no significant difference
in OS between smoking and non-smoking groups (median
survival time: 42.9 months vs. 49.7 months). Intriguingly,
we found that the eight-miRNA signature exhibited su-
perior performance in predicting the 5-year survival of pa-
tients with lung cancer who had never smoked or who had
ceased smoking more than 15 years ago. To examine the
difference in AUCs, we compared the clinical characteris-
tics between smoking and non-smoking groups. We found
the only significant correlation between smoking history
and clinicopathological features to be age. Smoking is more
common among young patients in TCGA LUAD cohort.
About 72.4 per cent (126 of 174) of TCGA LUAD patients
diagnosed at a young age (<or = 65 years), were current
smokers or reformed smokers of less than 15 years. How-
ever, there was no significant association of young age with
poor OS and we did not find-better AUC in young age
groups. This suggests that miRNA profile of the smoking-
and non-smoking-related lung cancer may be fundamen-
tally different, requiring further study. Previous reportshave shown that some of the eight miRNAs identified in
this study, such as miR-31 and miR-101, to be potential
cigarette smoke-mediated deregulated miRNAs in lung
cancer [60]. This prognostic miRNA signature classifier
for non-smoking-related LUAD may help clinicians to pin-
point those LUAD patients at high risk of unfavorable OS.
There are number of limitations to this study. A major
limitation was the lack of available information regarding
adjuvant therapy and EGFR mutation status, which defines
distinct molecular subsets of resected LUAD and also pre-
dicts whether tumors are sensitive to EGFR tyrosine kin-
ase inhibitors [53]. Such information is required to further
study the interaction between the prognostic effect of their
status and the miRNA signature. A further limitation was
that the TCGA LUAD cohort had a relatively short follow-
up period (median follow-up of 15 months) and the cen-
sored rate was high, which may affect the reliability of the
Kaplan-Meier estimates. There are also limitations in
obtaining all the data from a single source and randomly
assigning samples to training and testing sets for the de-
velopment and assessment of the prognostic model. Inde-
pendent external validation sets with long-term follow up
to provide a realistic assessment of the performance of this
miRNA signature would be more reliable.
Conclusions
We have identified a miRNA signature comprising eight
miRNAs (miR-31, miR-196b, miR-766, miR-519a-1, miR-
375, miR-187, miR-331 and miR-101-1), which can be used
as an independent prognostic marker of LUAD patient
survival. The independent prognostic model demonstrated
good performance in predicting 5-year survival, especially
in non-smokers. This signature may help to identify LUAD
patients at high risk of recurrence or metastasis, who may
benefit from adjuvant therapy. However, a number of limi-
tations to this study exist. The major limitation involves
the lack of available information regarding adjuvant ther-
apy. Such information is required to further study the
interaction between this miRNA signature and adjuvant
therapy. An independent validation of this miRNA signa-
ture is also required.
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